The Canadian patent covers Polyanhydrides which links low molecular weight drugs containing a carboxylic acid group and an amine, thiol, alcohol or phenol group within their structure into polymeric drug delivery systems.
The patent also covers methods of producing polymeric drug delivery systems through these polyanhydride linkers and methods of administering low molecular weight drugs to a host via the polymeric drug delivery systems.
Xenogenics believes it has applications in the company’s coated cardiac stent business and other therapeutic applications which may be attractive to the pharmaceutical industry.